| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
From gene expression profiling data of 130 Japanese pediatric AML patients registered in AML99 study, we found that EVI1 and MEL1 were overexpressed in approximately 30% of patients, and that their high expression was significantly associated with inferior survival. Because of their mutually exclusive expression, a combined evaluation of their high expression enabled a clear distinction of patients with inferior survival (P<0.00001 in EFS and OS). This association was confirmed by quantitative RT-PCR analysis of 81 patients registered in AML-05 study (P=0.00017 in EFS, P=0.00028 in OS). We believe that the combined estimation of EVI1 and MEL1 expression will be an effective method for risk stratification of pediatric AML patients.
|
